HemOnc Today Current Issue

The following articles appeared in the print edition of HemOnc Today.

Table of Contents

• ‘Negative experiences,’ lack of research impede cancer care in LGBTQ community
• Head and Neck Cancer Drugs in the Pipeline
• Value and P values John Sweetenham, MD, FRCP, FACP
• FDA approves Afinitor to treat advanced neuroendocrine tumors of gastrointestinal, lung origin
• FDA approves Gazyva plus bendamustine to treat follicular lymphoma
• FDA approves Idelvion for hemophilia B
• FDA approves Imbruvica for first-line CLL treatment
• FDA expands Ibrance approval for metastatic breast cancer
• Afatinib improves PFS in patients with brain metastases
• Bankruptcy increases risk for cancer mortality
• HPV serum antibodies predict OS, PFS rates in oropharyngeal cancer
• Increased frequency of unknown primary SCC linked to HPV–positive disease
• Lavage technique may detect early-stage ovarian, endometrial cancers
• Lenvatinib improves survival for patients with RCC who progressed after initial treatment
• Passive smoking increases risk for several diseases, health problems
• Pediatric-inspired chemotherapy superior to allogeneic HCT for younger adults with ALL
• Positive phase 3 trials more often cited, published in high-impact journals
• Rivaroxaban appears safe, effective in routine clinical practice
• Routine imaging during first complete remission fails to improve DLBCL survival
• Survival favorable among younger patients with rectal cancer despite having advanced disease
• Early, late initiation of ipilimumab induce similar response rates in unresectable or metastatic melanoma
• Intralesional therapy ‘here to stay’ for melanoma
• Local breast cancer recurrence risk decreases as event-free years increase
• Longer surgical interval shortens RFS when residual melanoma is present
• Surgery after immunotherapy may extend OS in patients with metastatic melanoma
• Talimogene laherparepvec, pembrolizumab combination safely treats advanced melanoma